Want to see MRKR full AI Analyst Report?
Marker Therapeutics (MRKR) Stock Statistics & Valuation Metrics
Total Valuation
Marker Therapeutics has a market cap or net worth of $14.89M. The enterprise value is $16.47M.
- Market Cap
- $14.89M
- Enterprise Value
- $16.47M
Share Statistics
Marker Therapeutics has 16,673,126 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 16,673,126
- Owned by Insiders
- 2.07%
- Owned by Institutions
- 5.76%
Financial Efficiency
Marker Therapeutics’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -76.65%.
- Return on Equity (ROE)
- -0.72
- Return on Assets (ROA)
- -0.64
- Return on Invested Capital (ROIC)
- -76.65%
- Return on Capital Employed (ROCE)
- -0.77
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.43M
- Employee Count
- 5
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Marker Therapeutics is -1.86. Marker Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -1.86
- PS Ratio
- 12.07
- PB Ratio
- 1.42
- Price to FCF
- -1.53
- Price to Operating Cash Flow
- -1.77
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Marker Therapeutics had revenue of 0 and earned -12.16M in profits. Earnings per share was -0.79.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -12.89M
- Pretax Income
- -12.18M
- Net Income
- -12.16M
- EBITDA
- -12.44M
- Earnings Per Share (EPS)
- -0.79
Cash Flow
In the last 12 months, operating cash flow was -9.76M and capital expenditures -8, giving a free cash flow of -9.76M billion.
- Operating Cash Flow
- -9.76M
- Free Cash Flow
- -9.76M
- Free Cash Flow per Share
- -0.51
Dividends & Yields
Marker Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -58.23%
- Earnings Yield
- -44.86%
Stock Price Statistics
- Beta
- 1.72
- 52-Week Price Change
- 1.36%
- 50-Day Moving Average
- 1.09
- 200-Day Moving Average
- 1.33
- Relative Strength Index (RSI)
- 41.03
- Average Volume (3m)
- 115.03K
Important Dates
Marker Therapeutics upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 24, 2027
- Ex-Dividend Date
- ―
Financial Position
Marker Therapeutics as a current ratio of 8.39, with Debt / Equity ratio of 0.00%
- Current Ratio
- 8.39
- Quick Ratio
- 8.39
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.29
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Marker Therapeutics has paid -15.16K in taxes.
- Income Tax
- -15.16K
- Effective Tax Rate
- 0.00
Enterprise Valuation
Marker Therapeutics EV to EBITDA ratio is -0.62, with an EV/FCF ratio of -0.56.
- EV to Sales
- 4.40
- EV to EBITDA
- -0.62
- EV to Free Cash Flow
- -0.56
- EV to Operating Cash Flow
- -0.56
Balance Sheet
Marker Therapeutics has $11.33M in cash and marketable securities with $0.00 in debt, giving a net cash position of $11.33M billion.
- Cash & Marketable Securities
- $11.33M
- Total Debt
- $0.00
- Net Cash
- $11.33M
- Net Cash Per Share
- $0.68
- Tangible Book Value Per Share
- $0.63
Margins
Gross margin is -320.83%, with operating margin of -868.95%, and net profit margin of -706.23%.
- Gross Margin
- -320.83%
- Operating Margin
- -868.95%
- Pretax Margin
- -707.46%
- Net Profit Margin
- -706.23%
- EBITDA Margin
- -707.46%
- EBIT Margin
- -707.46%
Analyst Forecast
The average price target for Marker Therapeutics is $9.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $9.00
- Price Target Upside
- 908.97% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- -56.64%
- EPS Growth Forecast
- 64.88%
Scores
- Smart Score
- ―
- AI Score
- 42
